Racial Disparities in Crohn's Disease Care: A Patient Guide

If you are a person of color living with Crohn's disease or ulcerative colitis, chances are you've felt - at least once - that the system wasn't built with you in mind. You are not imagining it. Peer-reviewed research now documents what many BIPOC patients have known for years: racial disparities in IBD affect who gets diagnosed, how quickly, what treatments are offered, and how well people fare after surgery. This article walks through the data honestly, names the gaps, and gives you practical tools to advocate for the care you deserve.

Key Takeaways

• IBD incidence among non-White patients in Minnesota rose 134% between 1970 and 2010, more than triple the 39% rise among White patients (1)
• BIPOC and Hispanic IBD patients face more than double the difficulty accessing specialists compared to White patients - 26% versus 11% (4)
• Black IBD patients over 65 use emergency departments nearly 1.5 times more often than White peers, reflecting gaps in outpatient care (2)
• 53% of BIPOC/Hispanic IBD patients report financial instability from their disease, versus 32% of White patients (4)
• Color of Gastrointestinal Illnesses (COGI), formerly Color of Crohn's, is a BIPOC-led nonprofit working to close these gaps through advocacy, research, and community (5)

The Hidden Inequity in IBD Care

Racial disparities in IBD are not a new phenomenon, but they are newly visible in the data. For decades, Crohn's disease and ulcerative colitis were framed as conditions that primarily affected White patients of European descent - and that framing shaped everything from clinical training to insurance algorithms to the demographics of research trials. The result is a healthcare landscape that still, in 2026, leaves BIPOC patients underdiagnosed, undertreated, and undersupported.

Why IBD Was Long Considered a "White Disease"

The myth has deep roots. Early epidemiological studies were conducted overwhelmingly in White, Western populations, and the resulting data was generalized as if it applied universally. Because the studies didn't look for IBD in communities of color, they didn't find it - and that absence was misread as evidence that the disease was rare in those groups. Clinicians trained on those datasets sometimes fail to consider IBD in BIPOC patients presenting with GI symptoms, defaulting instead to diagnoses like irritable bowel syndrome or infection.

The Demographic Shift in IBD Prevalence

The numbers tell a different story. IBD prevalence among non-Hispanic Black Americans nearly doubled from 0.32% to 0.5% between 1999 and 2015 (1). In Minnesota, IBD incidence among non-White patients grew 134% between 1970 and 2010 - more than triple the 39% rise among White patients over the same period (1). The disease was never exclusively White. The surveillance simply caught up. As diagnostic access broadens and awareness grows in diverse communities, these numbers will continue to rise - making equitable care not a niche concern but a central one for the entire IBD community.

Diagnostic Delays and Specialist Access

Timely diagnosis changes the trajectory of Crohn's disease. Early intervention can prevent complications, preserve bowel, and improve long-term quality of life. When diagnosis is delayed, the disease progresses silently - and the consequences compound.

The 12-Year Gap

Perhaps the most sobering statistic in this area: Black children with IBD have been documented to face diagnosis delays of up to 12 years after symptom onset (1). Twelve years of symptoms without a name. That delay isn't biological - it's systemic. It reflects clinicians who don't suspect IBD in children of color, families who lack access to pediatric gastroenterologists, and healthcare settings where complaints from Black patients are more likely to be minimized. We explored the broader problem of having your symptoms dismissed in our guide on medical gaslighting and self-advocacy in Crohn's disease, and the racial dimension adds another heavy layer.

Finding an IBD Specialist When You Are BIPOC

Access to a gastroenterologist who specializes in IBD is one of the strongest predictors of good outcomes. Yet BIPOC and Hispanic patients reported difficulty accessing IBD specialists at more than double the rate of White patients - 26% versus 11% (4). Asian and Hispanic adults received less outpatient gastroenterology care than White patients even after adjusting for socioeconomic factors (2). Geographic concentration of IBD specialists in majority-White areas compounds the problem. If your nearest specialist is two hours away and you can't take a day off work to get there, the treatment gap widens before anyone makes a clinical decision at all.

Treatment Gaps: Biologics, Steroids, and Emergency Care

The treatment you receive for Crohn's disease should depend on your disease, not on your race. But the data shows that BIPOC patients are less likely to receive the therapies most effective at controlling inflammation - and more likely to end up in the emergency department when those gaps take their toll.

Lower Biologic Utilization

Biologic therapies - drugs like infliximab, adalimumab, vedolizumab, and ustekinumab - represent the most significant advance in Crohn's treatment in decades. They can induce and maintain remission, heal the intestinal lining, and prevent the need for surgery. Yet Black patients historically received biologics, 5-aminosalicylates, and immunomodulators at significantly lower rates than White patients (1). The reasons are layered: implicit bias in prescribing, lack of specialist access, insurance barriers that fall harder on lower-income patients, and historic mistrust of the medical system rooted in real harm.

The Steroid and ED Cycle

When patients don't receive step-up therapies like biologics, they're often managed with corticosteroids - which control symptoms in the short term but carry serious long-term risks including bone loss, infections, diabetes, and cardiovascular complications. A 2025 Florida study of 10,578 patients found that non-Hispanic Black patients used steroids more frequently and visited the emergency department significantly more often than non-Hispanic White patients (3). Black Americans over 65 with IBD had nearly 1.5 times higher emergency department use compared to White peers (2). This pattern - lower access to maintenance therapy, higher reliance on steroids and emergency care - isn't a reflection of more aggressive disease. It's a reflection of a system that intervenes too late.

Social, Financial, and Emotional Toll

The disparities don't end at the clinic door. Living with Crohn's disease is expensive, exhausting, and emotionally demanding for everyone - but the burden is not evenly distributed.

Quality of Life Gaps

A 2024 online survey of IBD patients found that BIPOC and Hispanic patients reported poor symptom control at nearly twice the rate of White patients - 35% versus 18% (4). Health-related quality of life scores were significantly lower for BIPOC/Hispanic patients (41.3 versus 49.4 on a standardized scale) (4). These aren't abstract numbers. They represent daily pain, missed meals, canceled plans, and the grinding uncertainty of feeling unwell without confidence that your care team is managing your disease effectively.

Workplace and Financial Impact

IBD costs money - in direct medical expenses, in lost wages, in career compromises. But the financial hit is disproportionate. Among BIPOC/Hispanic IBD patients surveyed, 53% reported financial instability from their disease, compared with 32% of White patients (4). Half of BIPOC/Hispanic respondents said IBD negatively affected their employment, versus a third of White respondents (4). If you're navigating these financial pressures, our financial planning guide for Crohn's disease offers practical strategies - though we recognize that individual planning can only partially offset systemic inequities. For workplace-specific challenges, our article on navigating work and career with Crohn's disease covers accommodations, disclosure decisions, and legal protections.

Only 36% of BIPOC/Hispanic patients reported having access to emotional support, compared with 63% of White patients (4). That gap matters. Chronic illness is isolating on its own; when your experience is also invisible in the dominant patient narrative, the isolation deepens. Representation in support communities - seeing people who look like you and share your lived experience - isn't a luxury. It's a clinical need.

Surgical Outcomes and Postoperative Disparities

When Crohn's disease requires surgery - whether for strictures, fistulas, abscesses, or disease that hasn't responded to medication - equitable outcomes should be the baseline expectation. The data, unfortunately, shows otherwise.

Higher Complication Rates

Black, Hispanic, and Asian patients undergoing colorectal surgery for IBD experienced higher postoperative complications, more readmissions, and longer hospital stays than White patients (1). These outcomes persist even after adjusting for disease severity, which points to system-level causes rather than biological ones: disparities in hospital quality, surgical volume, postoperative follow-up, and the accumulating disadvantage of delayed diagnosis and inadequate maintenance therapy that precedes the decision to operate. Understanding treatment options across different healthcare systems - something we discussed in our piece on Crohn's disease treatment around the world - highlights how structural factors shape outcomes far more than individual biology.

If you are facing surgery, it is worth asking your care team explicitly about their complication rates, what the postoperative follow-up plan looks like, and whether a higher-volume IBD surgical center is an option.

Advocacy Organizations and Self-Advocacy Tools

The data in this article is heavy. It can feel paralyzing to read about systemic problems when what you really want is to feel better and get good care today. The good news is that organizations exist specifically to close these gaps, and there are concrete steps you can take in your own care.

Color of Crohn's and COGI

Color of Crohn's and Chronic Illness (COCCI), now known as Color of Gastrointestinal Illnesses (COGI), is a BIPOC-focused 501(c)(3) nonprofit launched in 2019 to improve quality of life for patients of color living with IBD and digestive disorders (5). COGI was founded by Melodie Narain-Blackwell, who was herself diagnosed with Crohn's disease at age 36 after presenting symptoms since age 6 - a personal experience that mirrors the diagnostic delays documented across the research (5).

COGI runs the annual Equity in GI Patient Symposium, the "Count Me In(cluded)" research diversity initiative, and the Comin' In H.O.T. podcast (5). If you're looking for a community that centers your experience rather than treating it as an afterthought, COGI is a strong starting point.

How to Self-Advocate for Equitable Care

Self-advocacy is not a substitute for systemic change, but it is a tool you can use right now. Here are concrete steps grounded in what the research shows matters:

• Keep a detailed symptom log. Documented patterns are harder to dismiss than verbal descriptions. Track frequency, severity, diet, stress, and medication timing.
• Request a second opinion. If your symptoms are being attributed to stress, IBS, or "nothing serious" and you're not improving, you have every right to see another provider - preferably a gastroenterologist who specializes in IBD.
• Ask specifically about biologic options. If you're being managed primarily with steroids and haven't been offered biologics or immunomodulators, ask why. The answer should be clinical, not logistical.
• Bring a trusted advocate to appointments. A family member, friend, or patient advocate who can take notes, ask follow-up questions, and witness the interaction makes a measurable difference.
• Document dismissive interactions. If a provider minimizes your symptoms, attributes them to anxiety, or refuses to order tests without a clear clinical rationale, write down what happened, when, and who was present.
• If you suspect medical gaslighting based on race, age, or gender, you are not imagining it. The data in this article backs you up. Trust your experience.

Frequently Asked Questions

Is Crohn's disease more common in certain racial groups?

Historically, IBD was considered most prevalent among White populations of European descent. However, IBD incidence is rising fastest among non-White groups. Among non-White patients in Minnesota, incidence rose 134% between 1970 and 2010 compared to 39% among White patients (1). The disease affects every racial and ethnic group.

Why do BIPOC patients get diagnosed later with Crohn's disease?

Diagnostic delays for BIPOC patients stem from several systemic factors: the outdated belief that IBD is a "White disease," fewer IBD specialists in communities of color, and documented patterns of symptom dismissal in clinical settings. Black children have faced delays of up to 12 years (1). These are system failures, not patient failures.

Are Black patients less likely to receive biologic therapy for IBD?

Yes. Research consistently shows that Black patients receive biologics, immunomodulators, and 5-aminosalicylates at lower rates than White patients (1). This gap is driven by prescribing patterns, specialist access, insurance barriers, and historic medical mistrust - not by differences in disease biology.

What is COGI (Color of Gastrointestinal Illnesses)?

COGI, formerly known as Color of Crohn's and Chronic Illness, is a 501(c)(3) nonprofit focused on improving quality of life for BIPOC patients living with IBD and digestive disorders. Founded in 2019, COGI runs patient symposiums, research diversity initiatives, and the Comin' In H.O.T. podcast (5). Visit colorofgi.org to learn more.

How can I advocate for better care as a BIPOC IBD patient?

Keep a detailed symptom log, request second opinions when symptoms are dismissed, ask specifically about biologic therapies, bring an advocate to appointments, and document any interactions where your concerns are minimized. Organizations like COGI offer community support and resources tailored to patients of color.

Do racial disparities affect surgical outcomes in Crohn's disease?

Yes. Black, Hispanic, and Asian patients undergoing colorectal surgery for IBD experience higher complication rates, more readmissions, and longer hospital stays than White patients - even after adjusting for disease severity (1). Ask your surgical team about their outcomes and whether a high-volume IBD center is accessible to you.

Are there clinical trials focused on reducing IBD disparities?

Research awareness is growing. COGI's "Count Me In(cluded)" initiative specifically works to increase BIPOC representation in IBD research (5). When considering a clinical trial, ask whether the study is actively recruiting diverse participants and whether the protocol accounts for disparities in access and follow-up.

References

1. Borum, M.L. Racial and Ethnic Disparities in Inflammatory Bowel Disease. Gastroenterology & Hepatology, 2023;19(5). Read study
2. Segura, S., et al. Association of Race and Ethnicity With Healthcare Utilization for Inflammatory Bowel Disease in the United States: A Retrospective Cohort Study. American Journal of Gastroenterology, April 2025. View on PubMed
3. Hussain, T., et al. Healthcare Utilization and Geographic Distribution of Advanced Therapy in Minority Race and Ethnic Groups With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, February 2025. View on PubMed
4. Shah, R., et al. Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey. Inflammatory Bowel Diseases, 2024;30(9):1467-1474. Read study
5. Color of Gastrointestinal Illnesses (COGI). Visit COGI
6. Disparities in U.S. Inflammatory Bowel Disease Care Revealed. Inside Precision Medicine, April 2025. Read article